SMMT Summit Therapeutics PLC
Company Analysis
Latest News
Summit Starts Phase II/III Trial of Ivonescimab for First-Line Biliary Cancer
Summit Therapeutics and partner Akeso Inc. have initiated EA2251, a Phase II/III study evaluating ivonescimab as a first-line treatment for advanced biliary...
🔴 Summit Therapeutics is trading 5% down in pre-market amid S&P 500 and Nasdaq declines
Summit Therapeutics is trading at $15.02, down 5.10%, with broad risk-off sentiment potentially contributing. - The S&P 500 was down 1.11% and the Nasdaq...
Summit Therapeutics Proposes Doubling Authorized Shares to Support Preferred Conversion
Summit Therapeutics has proposed an amendment to its charter that would double the number of authorized common shares from 1 billion to 2 billion. Shareholders...
🟢 Summit Therapeutics is trading 5% up today amid broader market rebound
Summit Therapeutics is trading at $15.39, up 5.19%; no direct cause for the move is established. - On October 19, the company announced a global Phase II...
Summit Therapeutics PLC Q3 2026 Earnings Preview: What Analysts Expect on October 19, 2026
Summit Therapeutics is expected to report a Q3 2026 net loss of $0.28 per share on zero revenue, as the stock trades at $21.42 against a bullish consensus...
🔴 Summit Therapeutics is trading 4.13% down today amid biotech and broader market selling
Summit Therapeutics is trading at $14.73 (-4.13%) amid biotech-sector weakness and broader market selling. - The supplied data show XBI fell 2.06% during the...
🔴 Summit Therapeutics is trading 4.23% down today with no clear company-specific catalyst
Summit Therapeutics is trading 4.23% down at $16.41 on October 13, 2026, with no clear company-specific announcement explaining the decline in available search...
🔴 Summit Therapeutics is trading 4.5% down today alongside declines in major indexes
Summit Therapeutics is trading at $17.14, down 4.51%, amid broader market weakness; the exact cause of the decline is not established. - No new...
🟢 Summit Therapeutics is trading 5% up today
Summit Therapeutics is trading 4.82% higher at $18.14 on October 7, 2026, with no clear company-specific reason for the intraday gain identified in available...
🔴 Summit Therapeutics is trading 4.2% down today amid a 2.50% XBI decline
Summit Therapeutics is trading 4.2% lower at $16.55 amid biotech-sector pressure, with the XBI down 2.50% during the session. - No new company-specific...
🟢 Summit Therapeutics is trading 4.03% up today after AstraZeneca completed its $2 billion equity investment
Summit Therapeutics is trading 4.03% up at $17.43 on October 5, 2026, after announcing AstraZeneca completed its $2 billion equity investment; the announcement...
Summit Teams With AstraZeneca, Daiichi Sankyo on Phase III Breast Cancer Trial
Summit Therapeutics has signed a clinical trial collaboration agreement with AstraZeneca and Daiichi Sankyo to evaluate its investigational drug ivonescimab...
🟢 Summit Therapeutics is trading 4.5% up today after AstraZeneca’s $2 billion investment
Summit Therapeutics is trading at $17.13, up 4.51% on September 30, 2026, following AstraZeneca’s $2 billion equity investment and collaboration on cancer-drug...
🟢 Summit Therapeutics is trading 13.4% up today after AstraZeneca’s $2 billion investment
Summit Therapeutics is trading 13.44% higher at $17.56 after AstraZeneca agreed to invest $2 billion and collaborate on cancer-treatment trials. - The...
Summit Therapeutics Announces $2.0 Billion Strategic Equity Investment from AstraZeneca
Summit Therapeutics entered into a securities purchase agreement with AstraZeneca Holdings B.V. for a private placement expected to generate $2.0 billion in...
AstraZeneca Bets $2 Billion on Summit Therapeutics — But Can a Pre-Revenue Biotech Justify a $17 Billion Valuation?
Shares of Summit Therapeutics surged 22.6% to $18.98 after AstraZeneca announced a $2 billion convertible preferred-share investment and clinical...
🟢 Summit Therapeutics is trading 22.6% up in pre-market after AstraZeneca announced a $2 billion strategic investment
Summit Therapeutics is trading 22.61% higher at $18.98 in pre-market after AstraZeneca’s $2 billion investment announcement. - The preferred shares convert at...
AstraZeneca Invests $2 Billion in Summit to Advance Cancer Drug
AstraZeneca will invest $2 billion in Summit Therapeutics through convertible preferred shares. The shares will convert at $18.36 per common share, a premium...
🟢 Summit Therapeutics is trading 16.3% up in after-hours trading with no confirmed new catalyst
Summit Therapeutics is trading 16.3% higher after hours at $18.00, with no new company announcement after the close confirmed in sources reviewed. - This...
🔴 Summit Therapeutics is trading 4.4% down; no clear company-specific catalyst identified
Summit Therapeutics is trading at $15.66, down 4.40%, with no clear company-specific catalyst identified for the September 25 decline. - The company’s latest...